Contact
searchSearch
HMP Global

Advertisement

Advertisement

ADVERTISEMENT

February 2014 - FRMC

Cost Savings with Bortezomib, Cyclophosphamide, and Dexamethasone
02/19/2014

Tim Casey

Tim Casey
New Orleans—Patients with untreated multiple myeloma had a cost savings of approximately $29,000 per treatment course if they received bortezomib, cyclophosphamide, and dexamethasone (BCD) compared with a group taking bortezomib,...
New Orleans—Patients with untreated multiple myeloma had a cost savings of approximately $29,000 per treatment course if they received bortezomib, cyclophosphamide, and dexamethasone (BCD) compared with a group taking bortezomib,...
New Orleans—Patients with...
02/19/2014
First Report Managed Care
Omacetaxine for CML
02/19/2014

Tim Casey

Tim Casey
New Orleans—After at least 24 months of follow-up, heavily pretreated patients with chronic phase or accelerated phase chronic myeloid leukemia (CML) had clinically meaningful and durable responses to omacetaxine, according to a subset...
New Orleans—After at least 24 months of follow-up, heavily pretreated patients with chronic phase or accelerated phase chronic myeloid leukemia (CML) had clinically meaningful and durable responses to omacetaxine, according to a subset...
New Orleans—After at least 24...
02/19/2014
First Report Managed Care
Dabigatran to Treat Patients with Acute Venous Thromboembolism
02/19/2014

Tim Casey

Tim Casey
New Orleans—A prespecified subgroup analysis of 2 randomized, phase 3 trials that included patients with acute venous thromboembolism (VTE) found that there was no difference in recurrent VTE or VTE-related mortality if they received...
New Orleans—A prespecified subgroup analysis of 2 randomized, phase 3 trials that included patients with acute venous thromboembolism (VTE) found that there was no difference in recurrent VTE or VTE-related mortality if they received...
New Orleans—A prespecified...
02/19/2014
First Report Managed Care
Treatment with Rituximab in Clinics and Offices versus Hospitals
02/19/2014

Tim Casey

Tim Casey
New Orleans—A retrospective analysis of a managed care claims database found that from 2007 to 2012, there was an increase in the proportion of patients who took rituximab to treat diffuse large B-cell lymphoma (DLBCL) in a hospital setting...
New Orleans—A retrospective analysis of a managed care claims database found that from 2007 to 2012, there was an increase in the proportion of patients who took rituximab to treat diffuse large B-cell lymphoma (DLBCL) in a hospital setting...
New Orleans—A retrospective...
02/19/2014
First Report Managed Care
Phase 2 Trial of Obinutuzumab for Advanced DLBCL
02/19/2014

Tim Casey

Tim Casey
New Orleans—Patients newly diagnosed with diffuse large B-cell lymphoma (DLBCL) tolerated a regimen of obinutuzumab and chemotherapy, according to a phase 2, open label, multicenter, single arm trial. The authors mentioned preliminary results...
New Orleans—Patients newly diagnosed with diffuse large B-cell lymphoma (DLBCL) tolerated a regimen of obinutuzumab and chemotherapy, according to a phase 2, open label, multicenter, single arm trial. The authors mentioned preliminary results...
New Orleans—Patients newly...
02/19/2014
First Report Managed Care
Allogeneic HSCT and Cognitive Impairment
02/19/2014

Tim Casey

Tim Casey
Patients undergoing allogeneic hematopoietic stem cell transplantation had cognitive impairment on executive function, processing speed, and verbal fluency.
Patients undergoing allogeneic hematopoietic stem cell transplantation had cognitive impairment on executive function, processing speed, and verbal fluency.
Patients undergoing allogeneic...
02/19/2014
First Report Managed Care
Economic Benefit Suggested with Abatacept for RA
02/19/2014

Mary Beth Nierengarten

Mary Beth Nierengarten
  San Diego—Use of abatacept as first- or second-line treatment for patients with moderate-to-severe rheumatoid arthritis (RA) may have an economic benefit over other biologic disease-modifying antirheumatic drugs (DMARDs) agents, as...
  San Diego—Use of abatacept as first- or second-line treatment for patients with moderate-to-severe rheumatoid arthritis (RA) may have an economic benefit over other biologic disease-modifying antirheumatic drugs (DMARDs) agents, as...
  San Diego—Use of abatacept as...
02/19/2014
First Report Managed Care
Efficacy of Golimumab for Refractory RA Maintained Over 5 Years
02/19/2014

Mary Beth Nierengarten

Mary Beth Nierengarten
San Diego—Long-term outcomes show that golimumab maintains its efficacy for patients with active rheumatoid arthritis (RA) who failed prior biologic therapy with anti-tumor necrosis factor (TNF) therapy.
San Diego—Long-term outcomes show that golimumab maintains its efficacy for patients with active rheumatoid arthritis (RA) who failed prior biologic therapy with anti-tumor necrosis factor (TNF) therapy.
San Diego—Long-term outcomes...
02/19/2014
First Report Managed Care
Tofacitinib Monotherapy Offers Significant Benefits for Active RA
02/19/2014

Mary Beth Nierengarten

Mary Beth Nierengarten
San Diego—In patients with rheumatoid arthritis (RA), tofacitinib monotherapy significantly inhibits progression of structural damage, improves signs and symptoms of disease, and improves function over 2 years compared to patients treated...
San Diego—In patients with rheumatoid arthritis (RA), tofacitinib monotherapy significantly inhibits progression of structural damage, improves signs and symptoms of disease, and improves function over 2 years compared to patients treated...
San Diego—In patients with...
02/19/2014
First Report Managed Care

Department

Conference Insider
Ustekinumab for Patients with Active PsA Long-Term
02/19/2014

Mary Beth Nierengarten

Mary Beth Nierengarten
San Diego—The efficacy and safety of ustekinumab as treatment for active psoriatic arthritis (PsA) is maintained at 100 weeks follow-up, according to long-term data presented at the ACR/ARHP meeting.
San Diego—The efficacy and safety of ustekinumab as treatment for active psoriatic arthritis (PsA) is maintained at 100 weeks follow-up, according to long-term data presented at the ACR/ARHP meeting.
San Diego—The efficacy and...
02/19/2014
First Report Managed Care

Advertisement

Advertisement

Advertisement

FRMC Volume 21, Issue 2

Current Issue

June 2024
Volume 21
Issue 2
Current Issue
Issue Archive

Advertisement

Advertisement

What's Trending?

News
Report: Cancer Will Kill 13.2 Million a Year by 2030
06/02/2010
06/02/2010
First Report Managed Care
Literature Review: Opioid-Induced Constipation
03/16/2015
These studies focus on the causes, consequences, and management of opioid-induced constipation.
These studies focus on the causes, consequences, and management of opioid-induced constipation.
These studies focus on the...
03/16/2015
First Report Managed Care
News
New Standardized Insurance Forms Could Make Buying Easier
08/23/2011
08/23/2011
First Report Managed Care
News
FDA Approves Denosumab for New Indication
12/10/2014
The FDA approved denosumab for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.
The FDA approved denosumab for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.
The FDA approved denosumab for...
12/10/2014
First Report Managed Care
News
CMS Announces Voluntary Bundled Payment Model
01/10/2018
The CMS recently announced the launch of a new voluntary bundled payment model that will cover multiple specialties and care services.
The CMS recently announced the launch of a new voluntary bundled payment model that will cover multiple specialties and care services.
The CMS recently announced the...
01/10/2018
First Report Managed Care

Video Insights

Hayward
Videos
Evolving Health Care Contact Centers Into Drivers of Value-Based Care
07/31/2024
Discover how health care contact centers can transform into drivers of value-based care through AI, automation, upskilling agents, and rethinking workflows and metrics to improve patient outcomes and population health.
Discover how health care contact centers can transform into drivers of value-based care through AI, automation, upskilling agents, and rethinking workflows and metrics to improve patient outcomes and population health.
Discover how health care contact...
07/31/2024
First Report Managed Care
Lucille Accetta Headshot
Videos
Enhancing Patient Medication Adherence: Insights and Strategies From Asembia 2024
06/11/2024
Lucille Accetta, PharmD, MBA, MSPH, Senior Vice President of CVS Specialty Operations
Key stakeholders in the health care industry gathered to discuss prevalent topics at this year's Asembia annual summit. Medication adherence emerged as one of the most talked-about issues. In a session led by Lucille Accetta, PharmD, MBA,...
Key stakeholders in the health care industry gathered to discuss prevalent topics at this year's Asembia annual summit. Medication adherence emerged as one of the most talked-about issues. In a session led by Lucille Accetta, PharmD, MBA,...
Key stakeholders in the health...
06/11/2024
First Report Managed Care
Melissa Andel, Principal, CommonHealth Solutions, LLC
Videos
Navigating the Impact of the Inflation Reduction Act: Implications for Payers, Patients, and Manufacturers
05/24/2024
Melissa Andel, Principal, CommonHealth Solutions, LLC
Learn about the impacts of the Inflation Reduction Act on payers and patients, highlighting the changes in Medicare benefits and drug coverage coming in 2025 and 2026.
Learn about the impacts of the Inflation Reduction Act on payers and patients, highlighting the changes in Medicare benefits and drug coverage coming in 2025 and 2026.
Learn about the impacts of the...
05/24/2024
First Report Managed Care
Joe DePinto Headshot
Videos
Navigating Payment Models in the CGT Landscape: Insights and Innovations
05/21/2024
Joe DePinto, Head of Cell, Gene, and Advanced Therapies, McKesson
An expert discusses the evolution and challenges of payment models in the cell and gene therapy (CGT) space reviewed during his session at Asembia 2024.
An expert discusses the evolution and challenges of payment models in the cell and gene therapy (CGT) space reviewed during his session at Asembia 2024.
An expert discusses the...
05/21/2024
First Report Managed Care
Jennifer L. Mathieu Senior Vice President, Professional and Government Affairs at AMCP
Videos
Unlocking the Future of Managed Care Pharmacy: A Deep Dive into Federal Legislation and Regulations
05/15/2024
Jennifer L. Mathieu Senior Vice President, Professional and Government Affairs, AMCP
Learn about developments in federal legislation and regulations within the pharmacy landscape shaping the future of managed care in an interview with a session presenter from AMCP 2024.
Learn about developments in federal legislation and regulations within the pharmacy landscape shaping the future of managed care in an interview with a session presenter from AMCP 2024.
Learn about developments in...
05/15/2024
First Report Managed Care
Tejaswi Kompala
Videos
Personalizing Weight Loss Management With GLP-1 Agonists
04/05/2024

Featuring Tejaswi Kompala, MD, head of cardiometabolic clinical strategy, Teladoc 

Featuring Tejaswi Kompala, MD, head o...
Delve into the rising demand for anti-obesity medications, the complexities of obesity management, and the importance of personalized approaches in improving cardiometabolic health in this insightful interview.
Delve into the rising demand for anti-obesity medications, the complexities of obesity management, and the importance of personalized approaches in improving cardiometabolic health in this insightful interview.
Delve into the rising demand for...
04/05/2024
First Report Managed Care
Zaubler Headshot
Videos
Integrating Behavioral Health Services to Reduce ED Visits: Substance Use Disorder and Social Determinants of Health
03/27/2024

Featuring Tom Zaubler, MD, MPH, CMO at NeuroFlow

Featuring Tom Zaubler, MD, MPH, CMO a...
Join us for the continuation of an engaging two-part series showcasing an expert dedicated to reducing emergency department visits through the integration of behavioral health practices. Dr Zaubler will share invaluable insights into...
Join us for the continuation of an engaging two-part series showcasing an expert dedicated to reducing emergency department visits through the integration of behavioral health practices. Dr Zaubler will share invaluable insights into...
Join us for the continuation of...
03/27/2024
First Report Managed Care
Zaubler Headshot
Videos
Integrating Behavioral Health Services to Reduce ED Visits: Suicide Prevention and Preemptive Primary Care
03/25/2024

Featuring Tom Zaubler, MD, MPH, CMO at NeuroFlow

Featuring Tom Zaubler, MD, MPH, CMO a...
Come join us for the first installment of a captivating two-part series featuring an expert committed to minimizing emergency department visits through the implementation of behavioral health integrations. Dr Zaubler will offer valuable...
Come join us for the first installment of a captivating two-part series featuring an expert committed to minimizing emergency department visits through the implementation of behavioral health integrations. Dr Zaubler will offer valuable...
Come join us for the first...
03/25/2024
First Report Managed Care
Yash Prajapati
Videos
Navigating the Evolution of Digital Solutions in Health Care
02/27/2024

Featuring Yash Prajapati, consultant at ZS Associates 

Featuring Yash Prajapati, consultant ...
Join us in exploring the challenges and opportunities in the development, approval, and integration of digital therapeutic solutions with ZS Associates consultant Yash Prajapati.
Join us in exploring the challenges and opportunities in the development, approval, and integration of digital therapeutic solutions with ZS Associates consultant Yash Prajapati.
Join us in exploring the...
02/27/2024
First Report Managed Care
Mansur Shomali
Videos
Advancements and Challenges in Diabetes Management
02/27/2024

Featuring Mansur Shomali, MD, chief medical officer at Welldoc, endocrinologist at MedStar Health 

Featuring Mansur Shomali, MD, chief m...
Learn about the state of digital therapeutics for disease management such as diabetes care in terms of cost, outcomes, integration, and more with Dr Mansur Shomali, CMO at Welldoc.
Learn about the state of digital therapeutics for disease management such as diabetes care in terms of cost, outcomes, integration, and more with Dr Mansur Shomali, CMO at Welldoc.
Learn about the state of digital...
02/27/2024
First Report Managed Care

Subscribe to our eNewsletters!

First Report Managed Care Newsletter

February 2014 Volume 11 Issue 2

View Issue Archive
Editorial Correspondence

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement